ArticleParasites & vectors2026
Individual and spatial heterogeneity of praziquantel efficacy against Schistosoma mansoni within the context of repeated mass drug administration.
Article in Parasites & vectors, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors.
Funding
Abstract
backgroundSchistosomiasis control relies on the continued effectiveness of praziquantel (PZQ), yet individual and spatial heterogeneity in PZQ efficacy in the context of repeated mass drug administration (MDA) remains poorly understood. This study aimed to identify individual and spatial determinants of PZQ efficacy against Schistosoma mansoni in rural Uganda.
methodsWe studied 3870 participants aged 5-90 years from 52 villages in Pakwach, Buliisa, and Mayuge districts in Uganda. Participants were recruited to the SchistoTrack cohort in January-February of 2022 and 2023. Participants received PZQ and were followed up four to five weeks later to assess cure using Kato-Katz (KK) microscopy and point-of-care circulating cathodic antigen (POC-CCA) tests. Logistic regression models were used to identify predictors of cure, defined as a 100% egg reduction rate (ERR). We explored a comprehensive set of 18 sociodemographic, biomedical, water, sanitation, and hygiene, and spatial factors. Subgroup analyses were conducted for adults (aged 18-90) versus children (aged 5-17). Spatial autocorrelation in the outcome and model residuals was assessed using join count statistics and Moran's I.
resultsOf 3870 clinical participants, 3704 (95.7%) received PZQ, and 3395 of these had complete clinical data. Among the 3395 treated participants, 1406 (41.4%) were infected with S. mansoni at baseline. The overall cure rate (ERR of 100%) was 76.3%, ranging from 68.9% to 85.4% across districts. Higher odds of cure were associated with older age (OR 1.34) and lower baseline infection intensity (moderate/heavy vs light OR 0.39-0.61). Greater height was associated with lower odds of cure (OR 0.99), which was driven by adults. Compared with Mayuge district, participants in Western districts had lower odds of cure (OR 0.48-0.53). In children, greater distance to water sites with snail presence was linked to higher odds of cure (OR 1.05 per 100m). Results were similar when using POC-CCA outcomes. Spatial clustering of treatment outcomes was observed by district, but no residual spatial autocorrelation remained after accounting for district effects.
conclusionsIncorporating spatial analyses, refining dose assessment, and strengthening post-MDA monitoring may help maintain PZQ effectiveness and support sustainable schistosomiasis control efforts.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.